




		EMLc	ATC codes: <a href="#">A04AA01</a>
Indication	Palliative care	ICD11 code: <a href="#">QC7A</a>	
INN	Ondansetron		
Medicine type	Chemical agent		
List type	Core		
Formulations	Parenteral > General injections > IV: 2 mg per mL in 2 mL ampoule (ondansetron base, as hydrochloride) Oral > Liquid: 4 mg per 5 mL (ondansetron base) Oral > Solid: 4 mg (ondansetron base) ; 8 mg (ondansetron base)		
EML status history	First added in 2011 ( <a href="#">TRS 965</a> ) Changed in 2019 ( <a href="#">TRS 1021</a> ) Changed in 2021 ( <a href="#">TRS 1035</a> )		
Sex	All		
Age	Also recommended for children		
Age restriction	> 1 month		
Therapeutic alternatives	dolasetron (ATC codes: A04AA04) granisetron (ATC codes: A04AA02) palonosetron (ATC codes: A04AA05) tropisetron (ATC codes: A04AA03)		
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . 		
Wikipedia	<a href="#">Ondansetron</a> 		
DrugBank	<a href="#">Ondansetron</a> 		

### Summary of evidence and Expert Committee recommendations

Following the review of square box listings on the EML and EMLc, the Expert Committee recommended that dolasetron, granisetron, palonosetron and tropisetron be specified as therapeutic alternatives under the square box listing for ondansetron on the EML and EMLc.

